Univest
Univest
  • Markets

3 Crude Oil Producer, Pharmaceuticals Company and Specialty Chemicals Maker Stocks With a Strong Future Roadmap: Oil India, Ajanta Pharma and Clean Science and Technology

  • November 18, 2026
  • Posted by: Kunal Singla
  • Category: Best Stocks
No Comments
3 Crude Oil Producer, Pharmaceuticals Company and Specialty Chemicals Maker Stocks With a Strong Future Roadmap: Oil India, Ajanta Pharma and Clean Science and Technology

Oil India, Ajanta Pharma and Clean Science and Technology: ROE of 11.4% to 23.3% and FY22 to FY26 revenue CAGR of 7.3% to 12.9%. Prices as of 17 Nov 2026.

Quick Answer

The three crude oil, drug maker and chemical stocks to watch are Oil India, Ajanta Pharma and Clean Science and Technology. Their return on equity ranges from 11.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 12.9%. Ajanta Pharma leads on both return on equity at 23.3% and revenue growth at 12.9% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.

Crude oil, drug maker and chemical stocks let investors follow companies that serve a growing part of the Indian economy. Oil India, Ajanta Pharma and Clean Science and Technology cover a crude oil producer, a pharmaceuticals company and a specialty chemicals maker.

This list covers three crude oil, drug maker and chemical stocks with complete current figures: Oil India, Ajanta Pharma and Clean Science and Technology. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Crude Oil, Drug Maker and Chemical Stocks?
  • Crude Oil, Drug Maker and Chemical Stocks at a Glance
  • Why Do Crude Oil, Drug Maker and Chemical Stocks Have a Strong Roadmap in India?
  • Why Oil India Features Among These Crude Oil, Drug Maker and Chemical Stocks
  • Why Ajanta Pharma Features Among These Crude Oil, Drug Maker and Chemical Stocks
  • Why Clean Science and Technology Features Among These Crude Oil, Drug Maker and Chemical Stocks
  • Oil India vs Ajanta Pharma vs Clean Science and Technology on Key Financials
  • Key Risks to Check Before Investing in Crude Oil, Drug Maker and Chemical Stocks
  • Final Thoughts on Crude Oil, Drug Maker and Chemical Stocks
    • What are crude oil, drug maker and chemical stocks?
    • Which crude oil, drug maker and chemical stocks are covered in this list?
    • Why do crude oil, drug maker and chemical stocks have a strong future roadmap in India?
    • How has Oil India performed financially?
    • How has Ajanta Pharma performed financially?
    • How has Clean Science and Technology performed financially?
    • What risks should investors check before buying crude oil, drug maker and chemical stocks?
    • Is this list of crude oil, drug maker and chemical stocks investment advice?

What Are Crude Oil, Drug Maker and Chemical Stocks?

Crude oil, drug maker and chemical stocks are listed companies that produce crude oil and natural gas from fields in Assam and other basins, make branded medicines for India and global markets, and make performance chemicals for cosmetics, paints and pharma. Their earnings depend on oil prices, medicine demand and chemical orders.

Crude Oil, Drug Maker and Chemical Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Oil India 433.5 72,563 7.6 7.2 11.4 0.65
Ajanta Pharma 3,312.5 41,241 36.3 36.0 23.3 0.06
Clean Science and Technology 715.95 8,080 34.7 35.1 14.5 0.00

On valuation, Clean Science and Technology trades at a P/E below the industry P/E, while Oil India and Ajanta Pharma trade above it, which reflects the growth the market already expects. Readers comparing crude oil, drug maker and chemical stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in crude oil, drug maker and chemical stocks can use the coming numbers to test whether growth is holding.

Why Do Crude Oil, Drug Maker and Chemical Stocks Have a Strong Roadmap in India?

Crude oil, drug maker and chemical stocks have a strong roadmap in India because steady energy demand, rising demand for branded medicines and wider use of specialty chemicals keep widening the market for these companies.

  • Crude oil. The country needs home grown energy.
  • Pharmaceuticals. Doctors prescribe trusted brands.
  • Specialty chemicals. Brands need performance inputs.

Why Oil India Features Among These Crude Oil, Drug Maker and Chemical Stocks

Among the crude oil, drug maker and chemical stocks on this list, Oil India is a public sector company that explores for and produces crude oil and natural gas, mainly in Assam and other parts of the country, and it also operates a crude pipeline in the North East.

The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 72,563 crore. The stock trades at a P/E of 7.6, above the industry P/E of 7.2.

Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore.

Roadmap: The company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.

What to watch: Track crude oil prices, production volumes and progress on new exploration blocks.

Why Ajanta Pharma Features Among These Crude Oil, Drug Maker and Chemical Stocks

Among the oil producer, pharma brand and performance chemical shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%.

In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.

Why Clean Science and Technology Features Among These Crude Oil, Drug Maker and Chemical Stocks

Among the three companies on this list, Clean Science and Technology makes specialty chemicals including performance chemicals, pharma intermediates and FMCG chemicals using its own catalytic processes.

In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%.

Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1.

Roadmap: The company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.

What to watch: Watch new product launches and capacity utilisation at its newer plants.

Oil India vs Ajanta Pharma vs Clean Science and Technology on Key Financials

The table below sets the three crude oil, drug maker and chemical stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Oil India 27,048 35,877 7.3% 7,551 21.0%
Ajanta Pharma 3,457 5,625 12.9% 1,056 18.8%
Clean Science and Technology 715 989 8.5% 230 23.2%

Ajanta Pharma posts the highest return on equity in this group at 23.3%. Oil India has the largest FY26 revenue at Rs 35,877 crore, and Ajanta Pharma shows the fastest revenue growth with a 12.9% compound annual rate. A useful habit with crude oil, drug maker and chemical stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several upstream oil, formulations and specialty chemicals stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Oil India 9,006 13,236 47.0%
Ajanta Pharma 1,329 1,697 27.7%
Clean Science and Technology 256 291 13.4%

Key Risks to Check Before Investing in Crude Oil, Drug Maker and Chemical Stocks

Every theme carries risks that deserve a check before any decision. For these crude oil, drug maker and chemical stocks, the main points are: Long-term oil producer, pharma brand and performance chemical shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Oil and gas prices. Earnings follow crude oil, gas and refining margins.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Raw material and energy costs. Input prices can move margins in chemicals.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter crude oil, drug maker and chemical stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Crude Oil, Drug Maker and Chemical Stocks

Crude oil, drug maker and chemical stocks reward investors who follow demand trends, order books and margins together. Oil India, Ajanta Pharma and Clean Science and Technology each have a clear plan to grow. Based on the 17 November 2026 close, Oil India trades at Rs 433.5, Ajanta Pharma at Rs 3,312.5 and Clean Science and Technology at Rs 715.95. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these crude oil, drug maker and chemical stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track crude oil, drug maker and chemical stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are crude oil, drug maker and chemical stocks?

Ans. Crude oil, drug maker and chemical stocks are listed companies that produce crude oil and natural gas from fields in Assam and other basins, make branded medicines for India and global markets, and make performance chemicals for cosmetics, paints and pharma. Their earnings depend on oil prices, medicine demand and chemical orders. This list looks at three of them, Oil India, Ajanta Pharma and Clean Science and Technology, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.

Which crude oil, drug maker and chemical stocks are covered in this list?

Ans. This list covers Oil India, Ajanta Pharma and Clean Science and Technology. Based on the 17 November 2026 close, Oil India traded at Rs 433.5, Ajanta Pharma at Rs 3,312.5 and Clean Science and Technology at Rs 715.95. Their return on equity ranges from 11.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.3% to 12.9%.

Why do crude oil, drug maker and chemical stocks have a strong future roadmap in India?

Ans. Crude oil, drug maker and chemical stocks have a strong roadmap in India because steady energy demand, rising demand for branded medicines and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Crude oil. The country needs home grown energy. Pharmaceuticals. Doctors prescribe trusted brands. Specialty chemicals. Brands need performance inputs. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Oil India performed financially?

Ans. Revenue rose from Rs 27,048 crore in FY22 to Rs 35,877 crore in FY26, a compound annual growth rate of 7.3%. Net profit grew from Rs 7,040 crore in FY25 to Rs 7,551 crore in FY26, a rise of 7.3%. In the June 2026 quarter, revenue grew 47.0% year on year to Rs 13,236 crore, while net profit rose 96.8% to Rs 4,027 crore. The company has a return on equity of 11.4%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 72,563 crore. The stock trades at a P/E of 7.6, above the industry P/E of 7.2. Looking ahead, the company is stepping up exploration and development spending and building a presence in refining and clean energy through its group companies. Steady production supports earnings and dividends.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

How has Clean Science and Technology performed financially?

Ans. Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1. Looking ahead, the company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.

What risks should investors check before buying crude oil, drug maker and chemical stocks?

Ans. Investors should check a few risks before buying crude oil, drug maker and chemical stocks. Oil and gas prices. Earnings follow crude oil, gas and refining margins. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of crude oil, drug maker and chemical stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Ajanta Pharma Best Stocks Clean Science and Technology Crude Oil drug maker and chemical stocks formulations and specialty chemicals stocks Oil India oil producer pharma brand and performance chemical shares upstream oil
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply